Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586939 | 0.94 | ADRA2A (0.57) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL28689243 | 0.90 | KDM4E (0.61) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL8092836 | 0.84 | SIGMAR1 (0.76) | SIGMAR1 | |
| Trientine SCHEMBL29145946 | 0.83 | CA12 (0.58) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL5106498 | 0.82 | SIGMAR1 (0.54) | SIGMAR1 | |
| SCHEMBL12009648 | 0.81 | SIGMAR1 (0.78) | SLC6A2SIGMAR1ADORA3SLC6A4SLC6A3 | |
| SCHEMBL188244 | 0.81 | ADRA2A (0.73) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL11486199 | 0.80 | ESR1 (0.57) | ADRA2ASLC6A2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL6013974 | 0.80 | CA1 (0.50) | ADRA2ASLC6A2KDM4EALDH1A1HTR1A | |
| SCHEMBL5106215 | 0.80 | TAAR1 (0.59) | CYP2C19TAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449477-B2 | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | ELI LILLY AND COMPANY | 2007-02-15 | — | — | US | disclosed |
| EP-1689719-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054202-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | POLI, HRAS, CHUK | ADRA2A 4227/4885SLC6A2 1644/4885KDM4E 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.